Watching this week for the possibility of early decision?
$scPharmaceuticals (SCPH.US)$ sNDA Applied for October 2023! The FDA decision to expand the FUROSCIX drug indication to include New York Heart Association Class IV heart failure patients is scheduled for August 10, 2024!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
